CompletedPhase 2NCT05355766
Long-term Clinical Study of CN128 in Thalassemia With Sever Liver Iron Overloaded Patients
Studying Rare hereditary hemochromatosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Hangzhou Zede Pharma-Tech Co., Ltd.
- Principal Investigator
- Jianmin Luo, PhDFirst Affiliated Hospital of Guangxi Medical University
- Intervention
- CN128 Tablets(drug)
- Enrollment
- 16 enrolled
- Eligibility
- 16-60 years · All sexes
- Timeline
- 2022 – 2025
Study locations (1)
- The First Affiliated Hospital Of Guangxi Medical University, Nanning, Guangxi, China
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05355766 on ClinicalTrials.govOther trials for Rare hereditary hemochromatosis
Additional recruiting or active studies for the same condition.